Cargando…
复发性小细胞肺癌治疗进展
Small cell lung cancer (SCLC) is a highly malignant tumor. The initial treatment of radiotherapy and chemotherapy are more sensitive, high remission rate, but susceptible to drug resistance and relapse after treatment. Although the treatment of lung cancer has undergone enormous changes in recent ye...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973303/ https://www.ncbi.nlm.nih.gov/pubmed/28302222 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.03.08 |
_version_ | 1783326590521835520 |
---|---|
collection | PubMed |
description | Small cell lung cancer (SCLC) is a highly malignant tumor. The initial treatment of radiotherapy and chemotherapy are more sensitive, high remission rate, but susceptible to drug resistance and relapse after treatment. Although the treatment of lung cancer has undergone enormous changes in recent years, treatment for relapsed SCLC is still a difficult problem in clinical field. In view of the serious resistance of recurrent SCLC to the existing chemotherapeutic drugs, the research on recurrent SCLC around the world is focused on the clinical trial of new drug development, optimization of chemotherapy regimen and target drug development. This paper summarize and estimate studies and literature reports of chemotherapy and precision therapy for relapsed SCLC, hopefully it could help clinicians treat relapsed SCLC and give us clinical research direction for relapsed SCLC in the future. |
format | Online Article Text |
id | pubmed-5973303 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-59733032018-07-06 复发性小细胞肺癌治疗进展 Zhongguo Fei Ai Za Zhi 综述 Small cell lung cancer (SCLC) is a highly malignant tumor. The initial treatment of radiotherapy and chemotherapy are more sensitive, high remission rate, but susceptible to drug resistance and relapse after treatment. Although the treatment of lung cancer has undergone enormous changes in recent years, treatment for relapsed SCLC is still a difficult problem in clinical field. In view of the serious resistance of recurrent SCLC to the existing chemotherapeutic drugs, the research on recurrent SCLC around the world is focused on the clinical trial of new drug development, optimization of chemotherapy regimen and target drug development. This paper summarize and estimate studies and literature reports of chemotherapy and precision therapy for relapsed SCLC, hopefully it could help clinicians treat relapsed SCLC and give us clinical research direction for relapsed SCLC in the future. 中国肺癌杂志编辑部 2017-03-20 /pmc/articles/PMC5973303/ /pubmed/28302222 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.03.08 Text en 版权所有©《中国肺癌杂志》编辑部2017 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | 综述 复发性小细胞肺癌治疗进展 |
title | 复发性小细胞肺癌治疗进展 |
title_full | 复发性小细胞肺癌治疗进展 |
title_fullStr | 复发性小细胞肺癌治疗进展 |
title_full_unstemmed | 复发性小细胞肺癌治疗进展 |
title_short | 复发性小细胞肺癌治疗进展 |
title_sort | 复发性小细胞肺癌治疗进展 |
topic | 综述 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973303/ https://www.ncbi.nlm.nih.gov/pubmed/28302222 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.03.08 |
work_keys_str_mv | AT fùfāxìngxiǎoxìbāofèiáizhìliáojìnzhǎn AT fùfāxìngxiǎoxìbāofèiáizhìliáojìnzhǎn AT fùfāxìngxiǎoxìbāofèiáizhìliáojìnzhǎn |